SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cemtrex, Inc. engages in the provision of solutions in the technology industry. It operates through the following segments: Security, Industrial Services, and Cemtrex Corporate. The Security segment provides end-to-end security solutions to meet corporate, industrial, and governmental security challenges. The Industrial Services segment offers single-source expertise and services for rigging, millwrighting, in plant maintenance, equipment erection, relocation, and disassembly to diversified customers. The Cemtrex Corporate segment refers to the holding company of the other two segments. The company was founded on April 27, 1998 and is headquartered in Hauppauge, NY.

Cemtrex Inc.

Cemtrex is trending as traders discuss its high volatility and potential for a short squeeze, drawing comparisons to other recent high-flying stocks. Community members are actively debating entry points and whether the stock has the potential for a multi-day run, while also weighing the risk of dilution. The stock's significant price movement and trading volume are key factors driving the current interest.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending due to speculation surrounding a potential deal with Warner Bros. Discovery, with community discussions focusing on the implications of a possible bidding war and whether Netflix should pursue the acquisition. The stock's recent price action and high trading volume are also fueling the conversation, as investors weigh the potential impact of deal outcomes and external factors like political influence.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

GRRR is trending due to Gorilla Technology's recent strategic investment in Astrikos.ai, with community members expressing optimism about the company's growth potential in AI infrastructure. Discussions revolve around potential short squeezes, the impact of the investment on share price, and the company's ongoing litigation against alleged stock manipulation.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media is trending amid a flurry of community discussions, largely centered around political commentary and reactions to news articles related to Donald Trump and his associates. Concerns about potential conflicts of interest, business dealings, and legal issues are prominent talking points. The stock's performance and future prospects are being debated within the context of broader political sentiment.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community discusses its potential, particularly regarding upcoming events and partnerships, including integration with NatPay. While some express frustration with the price action, others remain optimistic, emphasizing Zebec's focus on real-world utility and long-term growth. The reduction in circulating supply is also a key talking point among investors.

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences Ltd.

Wave Life Sciences Ltd

WVE is trending due to promising data on its obesity drug candidate, showing potential for fat loss and muscle preservation, sparking significant market interest. The community is discussing the drug's potential to rival existing treatments and its convenient dosing schedule. A recent public offering has also fueled discussions about the company's future and potential for a short squeeze.

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The firm's product pipeline includes Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Redwood City, CA.

Exicure Inc

XCUR is trending due to positive Phase 2 trial results for its cancer treatment, leading to significant after-hours momentum. Community members are discussing the stock's low float and potential for a continued squeeze, drawing comparisons to other high-flying tickers. This surge occurs amidst a broader market environment where traders are actively seeking stocks with the potential for substantial gains.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

TWG is trending due to a significant price surge, fueled by momentum traders targeting low-float stocks. Community discussions revolve around its potential for continued gains and comparisons to other recent runners like $CETX and $SMX. Some traders are speculating about a possible after-hours surge, while others caution about the risks associated with Chinese stocks.

AlphaTime Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on September 15, 2021 and is headquartered in New York, NY.

AlphaTime Acquisition Corp

AlphaTime Acquisition Corp (ATMC) is trending after shareholders approved its merger with HCYC Group, a Hong Kong-based insurance brokerage, leading to a massive after-hours volume spike. Community discussion revolves around its low float, potential for a significant squeeze, and comparisons to other high-flying low float stocks. Some traders are noting the potential for substantial gains, while others caution about the risks associated with low-float plays and the overall market conditions.

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

Structure Therapeutics Inc - ADR

GPCR is trending due to strong data from its oral GLP-1 aleniglipron, with analysts suggesting it could be a takeover target, potentially by PFE or NVO. The community is discussing its efficacy (15.3% weight loss, clean liver) and potential advantages over competitors, while some express concerns about tolerability and liver enzyme safety. Overall, the stock's movement is fueled by optimism surrounding its prospects in the obesity treatment market, with some eyeing a target price of $10B.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Structure Therapeutics Stock Doubled and Then Some on Monday

Key PointsShareholders were extremely pleased by the biotech's latest news from the lab...

Mid Cap Stocks To Watch Today - December 8th

WAVE Life Sciences, ProShares UltraPro Short QQQ, AltC Acquisition, Direxion Daily TSLA Bull 2X Shares, and Structure Therapeutics are the five Mid Cap stocks to watch today, according to...

Pharmaceutical Stocks To Follow Today - December 8th

Eli Lilly and Company, Structure Therapeutics, and Pfizer are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of...

Medical Stocks To Watch Today - December 8th

WAVE Life Sciences, Eli Lilly and Company, and Structure Therapeutics are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly...

What's Going On With Structure Therapeutics (GPCR) Stock Today?

Shares of Structure Therapeutics are soaring Monday after the company reported positive topline data from a weight loss drug trial.read more...

Structure Therapeutics (NASDAQ:GPCR) Hits New 1-Year High - Still a Buy?

Structure Therapeutics (NASDAQ:GPCR) Sets New 52-Week High - Here's Why...

<ul class="summary-bullets"><li>The company stated that results from&nbsp;aleniglipron achieved a mean weight loss of 11.3%&nbsp;at 36 weeks&nbsp;in the&nbsp;Phase 2b ACCESS study.</li><li>In the ACCESS II study, the mean weight loss clocked was up to 15.3%.</li><li>Based on these results, aleniglipron will proceed into Phase 3 clinical development, the firm noted.&nbsp;</li></ul>Shares of Structure Therapeutics (GPCR) shot up over 30% pre-market on Monday after the company&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-reports-positive-topline-data-access">announced positive&nbsp;topline data</a> from an ACCESS clinical program of aleniglipron, a weight loss pill.&nbsp;“The topline results presented today show that aleniglipron is differentiated and delivered clinically meaningful, competitive and dose-dependent weight loss with a safety profile appropriate for chronic use in a disease that impacts millions of people,”&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-reports-positive-topline-data-access">said</a> Raymond Stevens, CEO of Structure Therapeutics.&nbsp;<h2 class="st-heading-2">Positive Results</h2>The firm’s drug achieved a mean weight loss of 11.3%&nbsp;at 36 weeks&nbsp;in the&nbsp;Phase 2b ACCESS study and up to 15.3% in the ACCESS II study. Following this, aleniglipron will proceed into Phase 3 clinical development, the company said.&nbsp;“The weight-lowering data from these ACCESS studies, without any evidence of a plateau by Week 36, are very encouraging—particularly weight loss of up to 15.3% in ACCESS II that hopefully will be confirmed in larger, longer-term studies,” Julio Rosenstock, MD, Chair of the ACCESS program Steering Committee, said in the note.&nbsp;Noting that obesity is a complex, chronic disease, the drug’s commercial availability could have a profound impact on patients globally, some stakeholders said.&nbsp;The news comes amid the rising popularity of obesity treatment drugs in the U.S., as smaller firms compete for market share with large global drugmakers such as Novo Nordisk and Eli Lilly. According to fresh&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/27/3195649/0/en/Anti-Obesity-Drugs-Market-Size-to-Reach-35-52-Billion-by-2032-Driven-by-Advancements-in-Weight-Management-Therapies-and-Rising-Obesity-Prevalence-SNS-Insider.html">data from SNS Insider</a>, the anti-obesity drugs market size is expected to grow at a compound annual growth rate (CAGR) of 25.59% to reach $35.52 billion by 2032.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around GPCR jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1293/156;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_08_at_7_35_59_PM_png_c05be465cf.webp" alt="On Stocktwits, retail sentiment around GPCR jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels." width="1293" height="156"></figure>One user expects GPCR’s share price to cross $50 on Monday and surge to over $100 by March 2026.&nbsp;<stembedurl>https://stocktwits.com/View2021/message/638471909</stembedurl><a href="https://stocktwits.com/symbol/GPCR">Shares of GPCR</a> are up over 68% in the last six months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com

Injections for weight loss with Semaglutide. An obese woman gives a hormone glucagon-like peptide-1 (GLP-1) injection into the abdomen with a pen syringe.

Why Did Structure Therapeutics Stock Surge Pre-Market Today?

Shares of Structure Therapeutics shot up over 30% in premarket trading after the company announced positive topline data for its new weight loss pill. 

Equity

Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Sold by Capital Fund Management S.A.

Capital Fund Management S.A. cut its holdings in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 82.0% in the 2nd quarter, according to its most recent disclosure...

GPCR
Structure Therapeutics Inc - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GPCR News

GPCRStructure Therapeutics Inc - ADR